Trusted source of information on Respiratory Disorders that includes articles, news, videos, animations, quizzes, calculators and drugs.

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

Jacques said the hyperbaric oxygen therapy (HBOT) goes beyond that to provide healing of pressurized oxygen to a variety of medical conditions. "Because when you have a wound, it's probably ...

It also has activity against 31 CFTR variants — carried by around 150 cystic fibrosis patients in the US — that are not responsive to the older combination therapy. The new combination was ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF ... the potential for Mediar to deliver a first-in-class therapy that more precisely treats IPF than existing drugs.

Please provide your email address to receive an email when new articles are posted on . This study investigated the 2011 and 2013 implementation of the Competitive Bidding Program (CBP).

The main underlying reason for waitlisting was chronic obstructive pulmonary disease or emphysema in most patients, followed by cystic fibrosis and interstitial lung disease. The main limitations ...

New breakthroughs in gene editing mean that cures for genetic diseases such as cystic fibrosis could be developed ... approval for a CRISPR gene editing therapy was handed out in the UK in ...

However, the disease progressively worsens, severely impacting the oxygen exchange process in the lungs. IPF is believed to be caused by a cycle of damage and healing in the lung tissues. When this ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.